1,721,293 research outputs found
Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial
No full textAbstract not availableHannah S. van Meurs, Parvin Tajik, Michel H.P. Hof, Ignace Vergote, Gemma G. Kenter, Ben Willem J. Mol, Marrije R. Buist, Patrick M. Bossuy
Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
No full textProtocol and SA
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Abstract CT135: INNOVATE: a phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma
No full textAbstract
Background
TTFields are a non-invasive, regional antimitotic treatment modality, which have been approved for the treatment of recurrent and newly diagnosed glioblastoma by the FDA. TTFields act by delivering intermediate frequency alternating electric fields to the tumor, and act predominantly by disrupting the formation of the mitotic spindle during metaphase and by dielectrophoretic dislocation of intracellular constituents during cytokinesis. The combination of TTFields and taxanes has demonstrated synergy in preclinical models. In vivo, TTFields led to a significant reduction in tumor volumes in a murine model of ovarian cancer. INNOVATE was the first trial testing TTFields (200kHz) in ovarian cancer patients.
Methods
Thirty-one recurrent platinum-resistant ovarian cancer patients were enrolled in the INNOVATE trial and treated with TTFields in combination with weekly paclitaxel. All patients had unresectable tumors, an ECOG performance score of 0-1 and measurable disease per RECIST criteria. Patients were required to be at least 4 weeks from surgery and patients with implanted electronic devices were excluded. The primary endpoint was the incidence and severity of treatment emergent adverse events. Secondary endpoints included progression free-survival, overall survival and radiological response rate. Evaluation was performed according to the RECIST 1.1 criteria every 8 weeks
Results
The median age was 60 (range – 45-77) and most patients (77%) had serous histology. 52% had an ECOG score of 0. The median number of prior chemotherapy regimens was 4.1 (range 1-11) and median time from diagnosis was 48.1 months. All patients were platinum-resistant (median platinum-free interval was 4 months. 97% of patients received prior taxane-containing regimens, 16% received prior bevacizumab and 58% received prior pegylated-liposomal doxorubicin (PLD). The mean number of treatment cycles was 5.5 for paclitaxel and 4.2 for TTFields. The median compliance of patients with TTFields in the first 3 months was 77%. Ten (32%) patients suffered from serious adverse events during the study, none were related to TTFields. Most patients were reported to have mild-moderate, TTFields-related skin irritation, and only two patients (6.4%) had severe-grade skin irritation. The median PFS was 8.9 months (95% CI 4.7, NA). PFS rate at 6 months was 57%. Of the evaluable tumors, 25% had partial response and another 46.4% stable disease – a clinical benefit of 71.4% (median duration of 6.9 months). The median OS was not reached.
Conclusions
TTFields concomitant to weekly paclitaxel are tolerable and safe in heavily pre-treated platinum-resistant ovarian cancer ovarian cancer patients, with promising progression-free and overall survival. A phase III trial is planned, testing the efficacy of TTFields combined with paclitaxel in recurrent ovarian cancer patients.
Citation Format: Ignace Vergote, Roger von Moos, Luis Manso, Cristina Sessa. INNOVATE: a phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT135. doi:10.1158/1538-7445.AM2017-CT135</jats:p
Abstract CT174: Phase III INNOVATE study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer (ENGOT-ov50/BGOG study groups)
No full textVariations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Abstract CT174: Phase III INNOVATE study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer (ENGOT-ov50/BGOG study groups)
No full text
- …
